Literature DB >> 1501273

RNA- and DNA-binding activities in hepatitis B virus capsid protein: a model for their roles in viral replication.

T Hatton1, S Zhou, D N Standring.   

Abstract

The hepatitis B virus capsid or core protein (p21.5) binds nucleic acid through a carboxy-terminal protamine region that contains nucleic acid-binding motifs organized into four repeats (I to IV). Using carboxy-terminally truncated proteins expressed in Escherichia coli, we detected both RNA- and DNA-binding activities within the repeats. RNA-binding and packaging activity, assessed by resolving purified E. coli capsids on agarose gels and disclosing their RNA content with ethidium bromide, required only the proximal repeat I (RRRDRGRS). Strikingly, a mutant in which four Arg residues replaced repeat I was competent to package RNA, demonstrating that Arg residues drive RNA binding. In contrast, probing immobilized core proteins with 32P-nucleic acid revealed an activity which (i) required more of the protamine region (repeats I and II), (ii) appeared to bind DNA better than RNA, and (iii) was apparently modulated by phosphorylation in p21.5 derived from Xenopus oocytes. Deletion analysis suggested that this activity may depend on an SPXX-type DNA-binding motif in repeat II. Similar motifs found in repeats III and IV may also function to bind DNA. On the basis of these observations, together with a reinterpretation of recent studies showing that capsid protein mutants cause defects in viral genome replication, we propose a model suggesting that hepadnavirus capsid proteins participate directly in the intracapsid reverse transcription of RNA into DNA. In this model, repeat I binds RNA whereas the distal repeats are progressively recruited to bind elongating DNA strands. The latter motifs may be required for replication to be energetically feasible.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501273      PMCID: PMC289076     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA.

Authors:  R C Hirsch; D D Loeb; J R Pollack; D Ganem
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

2.  Characterization of hepatitis B virus capsid particle assembly in Xenopus oocytes.

Authors:  S Zhou; S Q Yang; D N Standring
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

3.  Phosphorylation in the carboxyl-terminal domain of the capsid protein of hepatitis B virus: evaluation with a monoclonal antibody.

Authors:  A Machida; H Ohnuma; F Tsuda; A Yoshikawa; Y Hoshi; T Tanaka; S Kishimoto; Y Akahane; Y Miyakawa; M Mayumi
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

4.  5'-terminal sequences influence the segregation of ground squirrel hepatitis virus RNAs into polyribosomes and viral core particles.

Authors:  G H Enders; D Ganem; H E Varmus
Journal:  J Virol       Date:  1987-01       Impact factor: 5.103

5.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

6.  Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein.

Authors:  F Birnbaum; M Nassal
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

7.  Production of hepatitis B virus nucleocapsidlike core particles in Xenopus oocytes: assembly occurs mainly in the cytoplasm and does not require the nucleus.

Authors:  S L Zhou; D N Standring
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

8.  Identification of the hepatitis B virus factor that inhibits expression of the beta interferon gene.

Authors:  T M Whitten; A T Quets; R H Schloemer
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

9.  A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA.

Authors:  M Junker-Niepmann; R Bartenschlager; H Schaller
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

10.  A model for the hepatitis B virus core protein: prediction of antigenic sites and relationship to RNA virus capsid proteins.

Authors:  P Argos; S D Fuller
Journal:  EMBO J       Date:  1988-03       Impact factor: 11.598

View more
  93 in total

1.  The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen.

Authors:  T T Yuan; G K Sahu; W E Whitehead; R Greenberg; C Shih
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Interaction between hepatitis B virus core protein and reverse transcriptase.

Authors:  L Lott; B Beames; L Notvall; R E Lanford
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Nuclear import of hepatitis B virus capsids and release of the viral genome.

Authors:  Birgit Rabe; Angelika Vlachou; Nelly Panté; Ari Helenius; Michael Kann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-08       Impact factor: 11.205

4.  Competing hydrophobic and screened-coulomb interactions in hepatitis B virus capsid assembly.

Authors:  Willem K Kegel; Paul van der Schoot Pv
Journal:  Biophys J       Date:  2004-06       Impact factor: 4.033

5.  Net charge per residue modulates conformational ensembles of intrinsically disordered proteins.

Authors:  Albert H Mao; Scott L Crick; Andreas Vitalis; Caitlin L Chicoine; Rohit V Pappu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

6.  Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus.

Authors:  M Kann; W H Gerlich
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Recombinant human hepatitis B virus reverse transcriptase is active in the absence of the nucleocapsid or the viral replication origin, DR1.

Authors:  M Seifer; D N Standring
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

Review 8.  Revisiting Hepatitis B Virus: Challenges of Curative Therapies.

Authors:  Jianming Hu; Ulrike Protzer; Aleem Siddiqui
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

9.  Biosynthesis and biochemical properties of the hepatitis C virus core protein.

Authors:  E Santolini; G Migliaccio; N La Monica
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  Detection of an RNase H activity associated with hepadnaviruses.

Authors:  S M Oberhaus; J E Newbold
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.